^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Osteosarcoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    doxorubicin hydrochloride (Topoisomerase II inhibitor) +
    ifosfamide (Bifunctional alkylating agent) +
    methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/20/2020
    Excerpt:
    Osteosarcoma: First-line therapy (primary/neoadjuvant/adjuvant therapy or metastatic disease)…Other Recommended Regimens…Doxorubicin, cisplatin, ifosfamide, and high-dose methotrexate
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    Summary of recommendations...Treatment (locoregional and advanced disease)...Osteosarcoma...Doxorubicin, cisplatin, HD-MTX and ifosfamide have antitumour activity in OS [I, A].
    DOI:
    10.1093/annonc/mdy310